Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success
|
|
- Kelly Griffith
- 6 years ago
- Views:
Transcription
1 Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success Drug developers have long been under pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and the resulting generic competition. Current weak economic conditions have exacerbated these challenges with sweeping R&D staff and budget reductions. In order to remain competitive, drug-makers must now do more with less. Scope Detailed description of both effective and ineffective biotech transfer approaches. In-depth analysis of advantages and disadvantages of numerous biotech transfer relationships. Case studies illustrating best practices. Comprehensive discussion of offshore biotech transfers, particularly focusing on India and China. Forecasts of industry-wide biotech transfers through Research and analysis highlights The drug development industry is undergoing a significant change that may permanently re-shape product development activities. Many industry experts believe the industry is shrinking; at the very least, the focus is shifting from large in-house research teams to smart approaches, strategic outsourcing and technology transfer. Although cost-cutting has traditionally not been a concern for R&D departments, the current economic environment has brought expense-reduction programs into research labs. Most of the leading drug-makers have recently undertaken and/or are currently in the midst of broad R&D cost-cutting programs. Because drug-makers must continue to introduce new products, maintaining high productivity is key. Biotech tech transfer offers a means to achieve this by providing technology sponsors with access to new technologies.
2 Key reasons to purchase this research Understand the driving forces behind biotech tech transfer. Save time and money with the report's succinct compilation and analysis of current biotech tech transfer trends. Understand the reasons behind biotech tech transfer success and failure. Develop strategies to optimize biotech tech transfer methodologies and protocols. Learn how biotech tech transfer will evolve over the coming years and why.
3 Table of Contents Building Biotech Technology Transfer Opportunities Executive Summary 8 Overview of biotech tech transfer 8 Why biotech tech transfer deals fail 9 Strategies to ensure successful biotech tech transfer deals 10 The future of biotech tech transfer deals 11 Chapter 1 Overview of biotech tech transfer 14 Summary 14 The biotechnology industry today 15 Biotechnology technologies and techniques 15 Proliferation of investigational products 18 Funding issues 18 Need to partner to advance product development 19 The emergence of biotechnology brokers 20 Drug development challenges 21 More complicated disease targets 22 Escalating costs 22 Increased regulatory scrutiny 23 Diminished in-house R&D resources 24 Types of biotech tech transfer relationships 26 Academic R&D infusions 28 Biotech biotech deals 29 Pharma biotech alliances 30 Licensing 32 R&D collaborations 33 Sales, distribution and co-marketing agreements 33 Joint ventures 33 Acquisitions 34 Volume of recent deals 35 Relationship trends 51 Volume and value 51 Ownership 52 Conclusion 53 Chapter 2 Why biotech tech transfer deals fail 56 Summary 56 High failure rates 57 Symptoms of deal failure 57 Factors that do not affect deal failure 58 Implications of deal failure 59 Impact on technology developers 60 Impact on technology sponsors 61
4 Lost value of failed deals 61 Main causes of biotech tech transfer failure 62 Due diligence failures 64 Technology performance 66 Patent issues 67 Developer organization strength 67 Deal structure 69 Financial compensation 70 Management changes 71 Cultural differences 72 Project organization and expectations 74 Other preventable problems 76 Technology failure 77 Conclusion 77 Chapter 3 Strategies to ensure successful biotech tech transfer deals 80 Summary 80 Measures of success 81 Success for the technology developer 81 Success for the technology sponsor 82 Key biotech tech transfer strategies 82 Strategies for both technology developers and sponsors 82 Meeting technology challenges 82 Strategies for technology developers 85 Optimizing resources 85 Thinking like a customer 88 Working with professional tech transfer organizations 89 Prolific publishing 91 Strategies for technology sponsors 92 Thorough technology identification and due diligence 93 Structuring innovative deal terms 98 Addressing compensation issues 105 Fostering an entrepreneurial developer environment 105 Ensuring effective alliance management 106 Navigating cultural chasms 108 Addressing international intellectual property challenges 110 Conclusion 113 Chapter 4 The future of biotech tech transfer deals 116 Summary 116 Introduction 117 The future of drug development 117 Impact of the economy 119 US healthcare reform 120 Biosimilars 121 Biotechnology in
5 Where biotech fits into Big Pharma 125 Dedicated biotechnology companies 127 Biotech tech transfer deal trends Volume and value 130 Ownership 132 Intellectual property issues 133 Success rates 134 Conclusion 135 Index 136 List of Figures Figure 1.1: Frequency of biotech tech transfer deals by type of institution 27 Figure 1.2: Number and volume of biopartnering deals, Figure 1.3: Acquisitions as a proportion of biotech tech transfer deals, 53 Figure 2.4: Characteristics of biotech tech transfer failure causes 63 Figure 2.5: Relative importance to sponsor of technology developer 66 Figure 3.6: Strategies to optimize biotech tech transfer opportunities 83 Figure 4.7: Biopharmaceutical vs. other pharmaceutical sales, Figure 4.8: Impact of industry and economic trends on conventional and biotech drug developers, Figure 4.9: Relative importance of biotechnology for leading pharmaceutical companies, 2009 vs Figure 4.10: Number and average size of global biotech companies, Figure 4.11: Number and volume of biopartnering deals, List of Tables Table 1.1: Definition of biotechnology techniques 17 Table 1.2: Biotech tech transfer deals, Table 1.3: Biotech tech transfer deals, 2009 (Contd.) 37 Table 1.4: Biotech tech transfer deals, 2009 (Contd.) 38 Table 1.5: Biotech tech transfer deals, 2009 (Contd.) 39 Table 1.6: Biotech tech transfer deals, 2009 (Contd.) 40 Table 1.7: Biotech tech transfer deals, 2009 (Contd.) 41 Table 1.8: Biotech tech transfer deals, 2009 (Contd.) 42 Table 1.9: Biotech tech transfer deals, 2009 (Contd.) 43 Table 1.10: Biotech tech transfer deals, 2009 (Contd.) 44 Table 1.11: Biotech tech transfer deals, 2009 (Contd.) 45 Table 1.12: Biotech tech transfer deals, 2009 (Contd.) 46 Table 1.13: Biotech tech transfer deals, 2009 (Contd.) 47 Table 1.14: Biotech tech transfer deals, 2009 (Contd.) 48 Table 1.15: Biotech tech transfer deals, 2009 (Contd.) 49 Table 1.16: Biotech tech transfer deals, 2009 (Contd.) 50 Table 3.17: Technology transfer areas of interest for Merck & Co., Table 3.18: Technology transfer areas of interest for Merck & Co., 2010 (Contd.) 96 Table 3.19: Novartis private equity fund holdings, Table 3.20: Novartis private equity fund holdings, 2010 (Contd.) 101
6 Table 3.21: Novartis private equity fund holdings, 2010 (Contd.) 102 Table 3.22: Novartis private equity fund holdings, 2010 (Contd.) 103 Table 4.23: Millions of older and overweight persons in the US and EU, Table 4.24: Biosimilars approved in the US and EU,
Building Biotech Technology Transfer Opportunities
For a clearer market perspective Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success Report Price Publication date 1995/ 2885/$3835 March 2010 H E A L T H C
More informationBuilding Biotech Technology Transfer Opportunities
HEALTHCARE Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry analyst with more than
More informationPatricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, (732)
Pharmaceutical Technology Patricia Van Arnum Issue Date: February 2012 Editor Contact: Patricia Van Arnum, pvanarnum@advanstar.com, (732) 346-3072 Biopharmaceutical Industry in 2012: Optimism on the Rise
More informationTrends and Transformations Facing Pharma in 2017
TH E Y E A R A H E A D : Trends and Transformations Facing Pharma in 2017 Table of Contents 2 Introduction Trend 1: The Rise of Generics Trend 2: Rx Volumes Spike Trend 3: Rise of Cold-Chain Logistics
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationValuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment
More informationERIC LAKE AND CHRIS SEIFARTH
ERIC LAKE AND CHRIS SEIFARTH Contents Introduction... 1 Determine What Relationship to Use... 2 Develop a Working Strategy... 3 Foster Team Environment and Collaboration... 5 What to Expect from Your CRO
More informationTechnology Transfer, Academic and Industry Cooperations
Technology Transfer, Academic and Industry Cooperations Jake Micallef PhD MBA COO ValiRx plc Visiting lecturer Simfonec Jake.micallef@valirx.com What do they want? Universities Money to fund research and
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationThe Commercial Use of Biodiversity: Access and Benefit Sharing in Practice.
The Commercial Use of Biodiversity: Access and Benefit Sharing in Practice. Session Objectives Overview Wide range of sectors undertaking research and developing commercial products from biodiversity Unique
More informationList of contributors List of abbreviations. 1 The business of healthcare innovation in the Wharton School curriculum 1
Contents List of contributors List of abbreviations page viii xiv xvii 1 The business of healthcare innovation in the Wharton School curriculum 1 Lawton Robert Burns 2 The pharmaceutical sector: rebooted
More informationEvolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors
HEALTHCARE Evolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors By Melissa Zebrowski Table of Contents Melissa Zebrowski Melissa Zebrowski has seven years of experience
More informationCutting Edge Information
Cutting Edge Information http://www.marketresearch.com/cutting Edge Information v3179/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday:
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More information2017 Clinical Trials Data Library
2017 Clinical Trials Data Library Copyright 2017 CenterWatch. Investigator Databank Total Active Principal Investigators Worldwide Active Investigators Worldwide Global Distribution of Investigative Sites
More informationHealthcare & Lifesciences Whitepaper
Healthcare & Lifesciences Whitepaper 1 Introduction Healthcare and Life Sciences (HLS) organizations are committed towards enhancing the lives and well-being of people around the world. They have not been
More informationMcGraw-Hill/Irwin. Copyright 2011 by the McGraw-Hill Companies, Inc. All rights reserved.
McGraw-Hill/Irwin Copyright 2011 by the McGraw-Hill Companies, Inc. All rights reserved. Chapter 8 Collaboration Strategies McGraw-Hill/Irwin Copyright 2011 by the McGraw-Hill Companies, Inc. All rights
More informationSustainable biotech innovation from an entrepreneur s perspective
www.azargen.com Sustainable biotech innovation from an entrepreneur s perspective Mauritz Venter Co-founder & CEO BIOSAFETY SYMPOSIUM 1 February 2018 The Biotech Dream GENETICS: THE MONEY RUSH IS ON The
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationCCA AGM 2013 Brussels, May In Health Science Logistics, is the Airport the Weakest Link?
CCA AGM 2013 Brussels, 14-15 May In Health Science Logistics, is the Airport the Weakest Link? PHARMA Pharmaceutical developments Of the 9 billion people in 2050 the share of older people will increase
More informationGlobal Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017
Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationPharmaceutical Innovation and Regulatory Data Protection Friends or Foes?
Pharmaceutical Innovation and Regulatory Data Protection Friends or Foes? Meir Pugatch, EIPIN Meeting, Munich, April 2015 meir.pugatch@maastrichtuniversity.nl Presentation overview The value of pharmaceutical
More informationBiosimilars Manufacturing- Cost reduction vitalities
Biosimilars Manufacturing- Cost reduction vitalities The Biopharmaceutical industry has emancipated a surge of growth over the past 20 years, primarily, due to blockbuster launches of novel biologics and
More informationValuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco
Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco Overview Introduction to Valuation Valuation of a Company / Therapeutic Product Valuation in Asia / HealthTech Asia's healthcare
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationEvolving Deal Terms: Recent Trends & How Far You Can Go LES Vancouver Chapter Luncheon June 2018
Evolving Deal Terms: Recent Trends & How Far You Can Go LES Vancouver Chapter Luncheon June 2018 Mark G. Edwards Managing Director Evolving Deal Terms: Recent Trends & How Far You Can Go A Quick Recap
More informationLandscape of the European Chemical Industry 2018
Ireland BioPharmaChem Ireland National contact Capital spending Direct employees 10 billion > 30,000 R&D investment 600 million Matt Moran Director General matt.moran@ibec.ie CHEMICAL INDUSTRY SNAPSHOT
More informationStrategies for attracting healthcare venture capital
Beth Silverstein MS, RAC is the Director of SciLucent, LLC, a USbased management, regulatory and technical services consulting firm dedicated to helping healthcare product companies maximise the value
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationambiguous insights through HCL s R&D Transformation limit your business
ambiguous insights through HCL s R&D Transformation limit your business Life Sciences industry is undergoing a transformational change - blockbuster patent expirations, global interconnected world, and
More informationWelcome to all Delegates Biotechnology for Pharmaceutical and Health Classification of Biotechnology Conventional Is a technique that makes use of living organism for specific purpose eg: bread/cheese
More informationDrug Discovery insights. Building
DDin Drug Discovery insights Building Bridges TO ACCELERATE DRUG DISCOVERY The Valley of death Basic Research Applied Research Technology Development & Demonstration Product Commercialization & Market
More informationBiotechnology Report CROATIA
Biotechnology Report CROATIA PREPARED BY AND IN 2009 Bulgaria Croatia Industry Report STATUS OF THE CROATIAN BIOTECHNOLOGY SECTOR (Financial data in ) 2 Total Biotech Companies 2 Biotech-Therapeutic 0
More informationEffective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationEffective Project Leadership and Management: Disclaimer
Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationSCP Workshop. Licensing & Health /////////// The real life / D. Immler
SCP Workshop Licensing & Health /////////// The real life 2018-12-04 / D. Immler Bayer is proud of its long-standing commitment to R&D Continuous Investment in R&D Projects Input Output Other 55 million
More informationContract Manufacturing of Biosimilars
Contract Manufacturing of Biosimilars Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production Huntington Beach, CA February
More informationImmatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been
More informationMarketspace. Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery
Mark J. Belsey spent his PhD looking at the role of cell signalling pathways underlying cell cycle progression in oncology. He is now working for the Competitive Intelligence healthcare team with Datamonitor,
More informationGrowing success in biotechnology. How a smart, connected facility cultivates innovation that improves output.
Growing success in biotechnology How a smart, connected facility cultivates innovation that improves output. 2 Growing success in biotechnology Introduction The global biotechnology sector is growing well.
More informationFocused pharma engineering
Focused pharma engineering When change is the only constant, are you up to speed? Welcome to the new pharma reality A major shift has taken place in the world of pharma manufacturing. The days when delivering
More informationFinancial Advisory. Valuation Services. Life Science Industry
Financial Advisory Services Life Science Industry Fact sheet: Life Science Industry Services Many life sciences companies struggle with nurturing the promise of innovative discoveries in a volatile market
More informationR&D Portfolio Planning In- and Out-licensing of Medicines
R&D Portfolio Planning In- and Out-licensing of Medicines Portfolio Planning Role of portfolio management Importance to Industry Tools, methods and models to make Go/No-Go decisions To help Prioritise
More informationCHARLTONS. New Rules Listing Biotech Companies on the Hong Kong Stock Exchange
CHARLTONS New Rules Listing Biotech Companies on the Hong Kong Stock Exchange 0 INTRODUCTION The Hong Kong Stock Exchange (the Exchange) published its Consultation Conclusions on a Listing Regime for Companies
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationAltraGen Senior management leadership offsite Day 1: Introduction
AltraGen Senior management leadership offsite Day 1: Introduction 0 AltraGen outsells its competitors because it offers what no one else can a complete product portfolio in pharmaceuticals Why we have
More informationReport of the Advisory Panel for Promotion of Medical Ventures (Summary)
Report of the Advisory Panel for Promotion of Medical Ventures (Summary) Report of the Advisory Panel for Promotion of Medical Ventures (Summary) Innovation is a key trigger for Japan s economic growth
More informationSUPERGENERICS BIOSIMILARS Biosimilars (Continued) TABLE 3 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS,
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 MARKET ANALYSES AND FORECASTS... 2 METHODOLOGY... 2 INTENDED AUDIENCE... 3 INFORMATION
More informationPharmaceutical Industry. Dr Gino Martini FRPharmS EIPG President
Challenges & Opportunities for the Pharmaceutical Industry Dr Gino Martini FRPharmS EIPG President Why do I enjoy being an Industrial Pharmacist? Something happened here Sir Alexander Fleming & his mouldy
More informationBIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3
BIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3 Bio Outsourcing Asia TABLE OF CONTENTS September 2008 Vol. 1 Issue 3 CanBiotech Inc. CHINA
More informationGlobal Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research
Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationPharmaceutical and Biotechnology Construction Sector Report - UK Analysis
Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis Published: 16/09/2016 / Number of Pages: 98 / Price: 795.00 Introduction and Overview The 3rd edition of the report'pharmaceutical
More informationChina and India have demonstrated their capability in good
JACOBSEN I am one of the youngest managers at NNE and I believe one of the reasons for this is how I have been able to learn and expand to keep up with how fast automation is growing. DOR Building a great
More informationView Report Details. Global Animal Health Market Report
View Report Details Global Animal Health Market Report ----------------------------------------- 2013 View Report Details Executive Summary Animal health market includes pharmaceuticals, vaccines and medicinal
More informationA New Approach to Outsourced Drug Development:
A New Approach to Outsourced Drug Development: How Sponsor-CRO Clinical Delivery Alliances Improve Performance Therapeutic Foresight. Trusted Results. Page 2 A New Approach to Outsourced Drug Development:
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationTransdermal Pain Management to 2020
Transdermal Pain Management to 2020 Products, Markets, Opportunities and Forecasts Greystone Research associates T r a n s d e r m a l P a i n M a n a g e m e n t t o 2 0 2 0 Industry Hierarchical Chain
More informationHong Kong Launches New Rules on Biotech Listings
Hong Kong Launches New Rules on Biotech Listings May 2018 The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies
More informationBIOPHARMACEUTICALS Availability, Diffusion, Sustainability. Massimo Riccaboni University of Florence & CERM, Rome
BIOPHARMACEUTICALS Availability, Diffusion, Sustainability Massimo Riccaboni University of Florence & CERM, Rome The need for a precise definition of biopharmaceutical products Since the 1980s, the general
More informationChapter 6 Discussion Questions
Chapter 6 Discussion Questions 1. What is the difference between a strength, a competitive advantage, and a sustainable competitive advantage? 2. What makes an ability (or set of abilities) a core competency?
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationPatient Protection and Affordable Care Act (H.R. 3590) Approval Pathway for Biosimilar Biological Products
Approval Pathway for Biosimilar Biological Products On December 24, 2009, the U.S. Senate passed the, its version of comprehensive healthcare reform legislation. On March 21, 2010, the U.S. House of Representatives
More informationprivate equity we do a great deal
private equity we do a great deal private equity there when it counts With one simple point of contact, you have access to a breadth of services and numerous advantages. Private equity groups demand a
More informationPatents & Health. Dr. Brian W Tempest.
Patents & Health Dr. Brian W Tempest www.briantempest.com Seminar on the Relationship between Patent Systems and the Availability of Medicines in Developing Countries and Least Developed Countries World
More informationCareer in Biotechnology Industry. Novartis Biocamp Roadshow
Career in Biotechnology Industry Novartis Biocamp Roadshow What is biotechnology? Biotechnology, often referred to as biotech, is the application of biological research techniques to create new processes
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Drug Discovery and Development Market in Asia - Introduction 3 Drug Discovery and Development Market in Asia - Overview 3.1 Introduction 3.1.1
More informationPromoting the Biotechnology Industry in Germany
Positions Promoting the Biotechnology Industry in Germany Germany s biotechnology industry ranks among the most sustainable and forward looking of today s cutting-edge technologies. Biotechnology is about
More informationThomas H. Byers Stanford University. Richard C. Dorf University of California, Davis. Andrew J. Nelson University of Oregon
' - ' ' " - Technology Ventures From Idea to Enterprise Thomas H. Byers Stanford University Richard C. Dorf University of California, Davis Andrew J. Nelson University of Oregon ^Connect Me I \ Learn 1
More informationEnsuring Quality & Regulatory Compliance when Collaborating with a Service Provider
DPT Thought Leadership Issue 2 Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider I N T R O D U C T I O N In recent years, the pharmaceutical industry has given greater
More informationThe Top 10 Pharma Companies in 2017
The Top 10 Pharma Companies in 2017 The Top 10 Pharma Companies in 2017 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationDATA INTELLIGENT BUILDINGS AND BIG CABA (CONTINENTAL AUTOMATED BUILDINGS ASSOCIATION) GREG WALKER, RESEARCH DIRECTOR
INTELLIGENT BUILDINGS AND BIG DATA CABA (CONTINENTAL AUTOMATED BUILDINGS ASSOCIATION) GREG WALKER, RESEARCH DIRECTOR NAVIGANT RESEARCH CASEY TALON, SENIOR RESEARCH ANALYST Table of Contents Section 1 Section
More informationEuropean Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai
European Biotech & Pharma Innovation Development Dr. Patrik Frei May 2014 Shanghai 1 Overview 1. Overview European Biotechs / Clusters 2. Trends in the Biotech & Pharma Venture Valuation: Independent assessment
More informationPharmaceutical Manufacturing and Process Analytical Technology
Pharmaceutical Manufacturing and Process Analytical Technology Trevor Murphy IMAR Technology Gateway Institute of Technology Tralee Tralee, Ireland Trevor.Murphy@research.ittralee.ie Abstract - Global
More informationMargins of pharmaceutical companies are continuing to decline the future lies in new ecosystems
Karin Mateu Media Relations Tel.: +41 (0) 58 286 44 09 karin.mateu@ch.ey.com Margins of pharmaceutical companies are continuing to decline the future lies in new ecosystems Glaxo is leading the way in
More informationPart I: Life Sciences Overview
Part I: Life Sciences Overview Biotechnology Introduction The Drug Development Process Genomics/Proteomics Agricultural Biotechnology Pharmaceuticals Market Size & Current Status Major Opportunities Major
More informationBioWorld s PARTNER in FOCUS: Open Innovations: Moscow
BioWorld s PARTNER in FOCUS: Open Innovations: Moscow GLOBAL BIOPHARMA INDUSTRY SEES OPPORTUNITY IN RUSSIA Top executives from companies as diverse at Medtronic, Pfizer, EADS, Google, Sanofi Pasteur and
More informationScienceDirect. Survey Framework for Understanding Value of Service
1 ScienceDirect Survey Framework for Understanding Value of Service 2 How we strive to help you This guide strives to provide our customers with framework to help identify the organizational value of having
More informationA French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
More informationCASE STUDY. A Competitive Intelligence Solution at a Large, Diversified Pharma
CASE STUDY A Competitive Intelligence Solution at a Large, Diversified Pharma Introducing a Joint Competitive Intelligence Solution from Cambridge Semantics and Thomson Reuters Competitive Intelligence
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationCURRICULUM SUMMARY COURSE DESCRIPTIONS & OUTLINES MENU MANUFACTURING INDUSTRIES INTRODUCTION TO MANUFACTURING OTHER INDUSTRIES ENERGY INDUSTRIES
CURRICULUM SUMMARY Cambashi s Manufacturing, Distribution and Energy off-the-shelf training courses, Cambashi- ItM, offer a consistent training solution for all your industries. Designed for sales, service,
More informationHematology Markets for Recombinant Therapies
Hematology Markets for Recombinant Therapies Products, Supply Chains, Markets, Players & Forecasts Report Brochure Greystone Research associates H e m a t o l o g y M a r k e t s f o r R e c o m b i n
More informationTHE MONTHLY RESEARCH CONFERENCE CALL HEALTHCARE: OPPORTUNITIES IN A STABILIZING SECTOR ARGUS MODERATOR. Jim Kelleher, CFA Director of Research
TH MONTHLY RSARCH CONFRNC CALL HALTHCAR: OPPORTUNITIS IN A STABILIZING SCTOR ARGUS MODRATOR Jim Kelleher, CFA Director of Research John M. ade Argus President David Toung Director of Healthcare Research
More informationInaugural Fraunhofer Delaware Technology Summit
Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu
More informationNew Health Data Economy: Strategic Partnerships with Life Sciences Company
New Health Data Economy: Strategic Partnerships with Life Sciences Company Pravin R Jadhav Sr. Director, Innovative Data Solutions Otsuka Data Sciences Otsuka Pharmaceutical Development and Commercialization
More informationThe Antipsychotic Drug Market to 2024
The Antipsychotic Drug Market to 2024 Products, Therapeutics Markets & Forecasts Report Brochure Greystone Research Associates is pleased to announce the publication of a new market assessment. Antipsychotics
More informationALPS Medical Breakthroughs ETF A primer for investors
ALPS Medical Breakthroughs ETF A primer for investors The ALPS Medical Breakthroughs ETF (NYSE Arca: SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance
More informationRealize the full value Use IT to drive results in pharma mergers, acquisitions, and divestitures. Viewpoint
Realize the full value Use IT to drive results in pharma mergers, acquisitions, and divestitures Viewpoint Table of contents M&A activity increasing 3 The pendulum swings 3 How IT can help this crucial
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationClinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013
Clinical Trials: Facts and Trends Dr Nik Nikitin Founder/Director, Russlan Clinical What is a clinical trial? A clinical trial is a research study in human volunteers to answer specific health questions
More information